Evidence map›Paper›PMID 27145085›Full record

ArticleVirulence2016

Enhanced detection of respiratory pathogens with nanotrap particles.

Nazly Shafagati, Katherine Fite, Alexis Patanarut, Alan Baer, Chelsea Pinkham, Soyeon An, Benjamin Foote, Benjamin Lepene, Kylene Kehn-Hall

Open access · goldAbstract read
In one paragraph

Article in Virulence, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed
0.7field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 32 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Comparison of NanotrapFrontiers in microbiology · 2023
    Article
  13. Article
  14. Article
  15. Nanotechnology-based antiviral therapeutics.Drug delivery and translational research · 2021
    Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Nazly Shafagatia National Center for Biodefense and Infectious Diseases, School of Systems Biology, George Mason University , Manassas , VA , USA.
Katherine Fitea National Center for Biodefense and Infectious Diseases, School of Systems Biology, George Mason University , Manassas , VA , USA.
Alexis Patanarutb Ceres Nanosciences Inc. , Manassas , VA , USA.
Alan Baera National Center for Biodefense and Infectious Diseases, School of Systems Biology, George Mason University , Manassas , VA , USA.
Chelsea Pinkhama National Center for Biodefense and Infectious Diseases, School of Systems Biology, George Mason University , Manassas , VA , USA.
Soyeon Ana National Center for Biodefense and Infectious Diseases, School of Systems Biology, George Mason University , Manassas , VA , USA.
Benjamin Footea National Center for Biodefense and Infectious Diseases, School of Systems Biology, George Mason University , Manassas , VA , USA.
Benjamin Lepeneb Ceres Nanosciences Inc. , Manassas , VA , USA.
Kylene Kehn-Halla National Center for Biodefense and Infectious Diseases, School of Systems Biology, George Mason University , Manassas , VA , USA.
George Mason University · USCeres Nanosciences · US

Funding

Nanotrap particle-based assay to quantify HIV-1 in latently-infected T cellsR21AI113140 · NIAID · GEORGE MASON UNIVERSITY · PI KASHANCHI, FATAH · 2014 to 2015
$409k
NIAID NIH HHS R21 AI113140
6 · The paper itself

Abstract

The Influenza virus is a leading cause of respiratory disease in the United States each year. While the virus normally causes mild to moderate disease, hospitalization and death can occur in many cases. There are several methodologies that are used for detection; however problems such as decreased sensitivity and high rates of false-negative results may arise. There is a crucial need for an effective sample preparation technology that concentrates viruses at low abundance while excluding resident analytes that may interfere with detection. Nanotrap particles are hydrogel particles that are coupled to chemical dye affinity baits that bind a broad range of proteins and virions. Within minutes (<30 minutes), Nanotrap particles concentrate low abundant proteins and viruses from clinically complex matrices. Nanotrap particles with reactive red baits concentrated numerous respiratory viruses including various strains and subtypes of Influenza virus, Coronavirus, and Respiratory Syncytial Virus from saliva, nasal fluid swab specimens, and nasal aspirates. Detection was enhanced more than 10-fold when coupled to plaque assays and qRT-PCR. Importantly, Nanotrap particle can efficiently capture and concentrate multiple viral pathogens during a coinfection scenario. These results collectively demonstrate that Nanotrap particles are an important tool that can easily be integrated into various detection methodologies.

Indexed as

CoinfectionCoronavirusCoronavirus InfectionsHumansInfluenza, HumanNanotechnologyNoseOrthomyxoviridaeRespiratory Syncytial VirusesRespiratory Tract InfectionsSalivadiagnosticsinfluenzananotrap particlesrespiratory pathogensrespiratory syncytial virusviruses

Identifiers

PMID27145085
PMCPMC5029303
OpenAlexW2347122218

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.